文献速递泌尿生殖腹部CT

定量计算机辅助诊断算法在多期多排CT上自动检测肾脏病灶峰值强化以鉴别透明细胞癌与乳头状癌、嫌色细胞癌、嗜酸细胞瘤及乏脂肪血管平滑肌脂肪瘤

Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography.
PubMed 文献 · Abdom Radiol (NY) · 2017-01-01

本研究纳入200例经病理证实的肾脏肿块患者,评估新型定量计算机辅助诊断(CAD)算法在多期多排CT上自动检测病灶峰值衰减的能力,以鉴别透明细胞肾细胞癌(ccRCC)与其他肾脏病变。在皮髓质期,CAD所得ROI鉴别ccRCC与嫌色细胞癌、乳头状癌、嗜酸细胞瘤及乏脂肪血管平滑肌脂肪瘤的AUC分别为0.850、0.959、0.792和0.825。Bland-Altman分析显示CAD与手动方法在各期均有良好一致性,平均差异为14至26 HU。

要点

  • CAD算法可在四期MDCT上自动勾画全病灶3D轮廓并检测峰值衰减ROI。
  • 皮髓质期CAD鉴别ccRCC与pRCC的AUC最高,达0.959。
  • CAD与手动ROI在各期平均差异为14至26 HU,一致性良好。

核心结论

  • 新型定量CAD算法能稳健检测肾脏病灶峰值HU,鉴别ccRCC与其他肾脏病变的性能与手动方法相当。

研究设计与样本

  • 回顾性查询临床数据库,纳入200例经组织学证实、术前接受四期(平扫、皮髓质期、肾实质期、排泄期)MDCT的肾脏肿块患者,共200个病灶;对所有四期图像勾画全病灶3D轮廓,CAD算法在3D轮廓内确定峰值衰减ROI,并以手动在视觉最强化部分放置的ROI及正常肾皮质ROI作为参考标准。

关键影像表现/征象

  • CAD算法在所有四期图像的全病灶3D轮廓内自动确定峰值衰减ROI。
  • 相对病灶衰减按公式[(峰值病灶衰减ROI-皮质ROI)/皮质ROI]×100%归一化至正常肾皮质。

诊断标准与关键数值

  • 皮髓质期CAD所得ROI鉴别ccRCC与chRCC的AUC为0.850(95%CI 0.732-0.968)。
  • 皮髓质期CAD所得ROI鉴别ccRCC与pRCC的AUC为0.959(95%CI 0.930-0.989)。
  • 皮髓质期CAD所得ROI鉴别ccRCC与嗜酸细胞瘤的AUC为0.792(95%CI 0.716-0.869)。
  • 皮髓质期CAD所得ROI鉴别ccRCC与fp-AML的AUC为0.825(95%CI 0.703-0.948)。
  • Bland-Altman分析显示CAD与手动方法在各期平均差异为14至26 HU,一致性优秀。

临床应用与阅片要点

  • CAD算法可自动检测病灶峰值衰减,性能与手动方法相当,可用于辅助鉴别ccRCC与其他肾脏病变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance of a novel, quantitative computer-aided diagnostic (CAD) algorithm on four-phase multidetector computed tomography (MDCT) to detect peak lesion attenuation to enable differentiation of clear cell renal cell carcinoma (ccRCC) from chromophobe RCC (chRCC), papillary RCC (pRCC), oncocytoma, and fat-poor angiomyolipoma (fp-AML).

MATERIALS AND METHODS: We queried our clinical databases to obtain a cohort of histologically proven renal masses with preoperative MDCT with four phases [unenhanced (U), corticomedullary (CM), nephrographic (NP), and excretory (E)]. A whole lesion 3D contour was obtained in all four phases. The CAD algorithm determined a region of interest (ROI) of peak lesion attenuation within the 3D lesion contour. For comparison, a manual ROI was separately placed in the most enhancing portion of the lesion by visual inspection for a reference standard, and in uninvolved renal cortex. Relative lesion attenuation for both CAD and manual methods was obtained by normalizing the CAD peak lesion attenuation ROI (and the reference standard manually placed ROI) to uninvolved renal cortex with the formula [(peak lesion attenuation ROI - cortex ROI)/cortex ROI] × 100%. ROC analysis and area under the curve (AUC) were used to assess diagnostic performance. Bland-Altman analysis was used to compare peak ROI between CAD and manual method.

RESULTS: The study cohort comprised 200 patients with 200 unique renal masses: 106 (53%) ccRCC, 32 (16%) oncocytomas, 18 (9%) chRCCs, 34 (17%) pRCCs, and 10 (5%) fp-AMLs. In the CM phase, CAD-derived ROI enabled characterization of ccRCC from chRCC, pRCC, oncocytoma, and fp-AML with AUCs of 0.850 (95% CI 0.732-0.968), 0.959 (95% CI 0.930-0.989), 0.792 (95% CI 0.716-0.869), and 0.825 (95% CI 0.703-0.948), respectively. On Bland-Altman analysis, there was excellent agreement of CAD and manual methods with mean differences between 14 and 26 HU in each phase.

CONCLUSION: A novel, quantitative CAD algorithm enabled robust peak HU lesion detection and discrimination of ccRCC from other renal lesions with similar performance compared to the manual method.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Coy H, Young JR, Douek ML, et al. Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography. Abdom Radiol (NY). 2017. PMID: 28280876. doi:10.1007/s00261-017-1095-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。